CONCLUSION: Intratympanic dexamethasone (ITD) within 1 month after initial treatment failure should be utilized as salvage treatment for refractory sudden sensorineural hearing loss (SSNHL). OBJECTIVE: To investigate the therapeutic efficacy over time of ITD as salvage treatment in SSNHL. MATERIALS AND METHODS: We retrospectively reviewed the medical records and audiograms of 99 SSNHL patients who were refractory to 2 weeks of oral steroid treatment, from August 2003 to October 2006. Patients were divided into those receiving no further treatment (control group) and those receiving ITD within 2 weeks (early-ITD), between 2 weeks and 1 month (mid-ITD), and between 1 and 2 months (late-ITD) after initial treatment failure. ITD was performed in the supine position on four separate occasions over the course of 2 weeks. Final assessment of hearing was carried out 3 months after outbreak of SSNHL. Hearing improvement was defined as a > 15 dB decrease in four-tone average (FTA). RESULTS: Overall hearing improvement was observed in 8 of 50 (16.0%) control patients, 7 of 16 (43.8%) early ITD patients, 6 of 20 (30.0%) mid ITD patients, and 2 of 13 (15.4%) late ITD patients.
CONCLUSION: Intratympanic dexamethasone (ITD) within 1 month after initial treatment failure should be utilized as salvage treatment for refractory sudden sensorineural hearing loss (SSNHL). OBJECTIVE: To investigate the therapeutic efficacy over time of ITD as salvage treatment in SSNHL. MATERIALS AND METHODS: We retrospectively reviewed the medical records and audiograms of 99 SSNHL patients who were refractory to 2 weeks of oral steroid treatment, from August 2003 to October 2006. Patients were divided into those receiving no further treatment (control group) and those receiving ITD within 2 weeks (early-ITD), between 2 weeks and 1 month (mid-ITD), and between 1 and 2 months (late-ITD) after initial treatment failure. ITD was performed in the supine position on four separate occasions over the course of 2 weeks. Final assessment of hearing was carried out 3 months after outbreak of SSNHL. Hearing improvement was defined as a > 15 dB decrease in four-tone average (FTA). RESULTS: Overall hearing improvement was observed in 8 of 50 (16.0%) control patients, 7 of 16 (43.8%) early ITDpatients, 6 of 20 (30.0%) mid ITDpatients, and 2 of 13 (15.4%) late ITDpatients.
Authors: Young Ho Kim; Kyung Tae Park; Byung Yoon Choi; Min Hyun Park; Jun Ho Lee; Seung-Ha Oh; Sun O Chang Journal: Eur Arch Otorhinolaryngol Date: 2011-12-08 Impact factor: 2.503
Authors: Jong Bin Lee; Seong Jun Choi; Keehyun Park; Hun Yi Park; Oak-Sung Choo; Yun-Hoon Choung Journal: Eur Arch Otorhinolaryngol Date: 2011-01-08 Impact factor: 2.503
Authors: Petros V Vlastarakos; George Papacharalampous; Paul Maragoudakis; George Kampessis; Nicholas Maroudias; Dimitrios Candiloros; Thomas P Nikolopoulos Journal: Eur Arch Otorhinolaryngol Date: 2011-08-19 Impact factor: 2.503
Authors: M Yamazaki; S Naganawa; M Tagaya; H Kawai; M Ikeda; M Sone; M Teranishi; H Suzuki; T Nakashima Journal: AJNR Am J Neuroradiol Date: 2011-12-15 Impact factor: 3.825